|
Active substance |
pembrolizumab |
|
Holder |
MSD Belgium BVBA/SPRL |
|
Status |
Closed |
|
Indication |
In combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in adults with a PDL-1 CPS score=0. |
|
Public documents |
|
|
Last update |
10/08/2020 |
Keytruda®
Last updated on 10/09/2024